 | • レポートコード：360iR22DE091 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、257ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査報告書では、2021年に117.6億ドルであった世界の骨粗鬆症治療＆骨折治療市場規模が、2022年に127.3億ドルになり、2027年まで年平均8.42%で成長して191.2億ドルに達すると予測しています。本報告書では、骨粗鬆症治療＆骨折治療の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物別（アレンドロネート、バイオホスホネート、イバンドロネート、リセドロネート、ゾレドロン酸）分析、投与経路別（注射剤、経口剤）分析、流通チャネル別（ドラッグストア、Eコマース、病院、プライベートクリニック、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の項目を掲載しています。本書に記載されている企業情報としては、Actavis plc、Amgen Inc.、Arthrex, Inc.、Bioventus Inc.、DJO Global, Inc.、Eli Lilly and Company、F.Hoffmann La Roche Ltd.、GlaxoSmithKline plc、ISTO Biologics、Johnson＆Johnson、Medtronic, plc、Merck and Company Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の骨粗鬆症治療＆骨折治療市場規模：薬物別 - アレンドロネートの市場規模 - バイオホスホネートの市場規模 - イバンドロネートの市場規模 - リセドロネートの市場規模 - ゾレドロン酸の市場規模 ・世界の骨粗鬆症治療＆骨折治療市場規模：投与経路別 - 注射剤の市場規模 - 経口剤の市場規模 ・世界の骨粗鬆症治療＆骨折治療市場規模：流通チャネル別 - ドラッグストアチャネルの市場規模 - Eコマースチャネルの市場規模 - 病院チャネルの市場規模 - プライベートクリニックチャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の骨粗鬆症治療＆骨折治療市場規模：地域別 - 南北アメリカの骨粗鬆症治療＆骨折治療市場規模 アメリカの骨粗鬆症治療＆骨折治療市場規模 カナダの骨粗鬆症治療＆骨折治療市場規模 ブラジルの骨粗鬆症治療＆骨折治療市場規模 … - アジア太平洋の骨粗鬆症治療＆骨折治療市場規模 日本の骨粗鬆症治療＆骨折治療市場規模 中国の骨粗鬆症治療＆骨折治療市場規模 インドの骨粗鬆症治療＆骨折治療市場規模 韓国の骨粗鬆症治療＆骨折治療市場規模 台湾の骨粗鬆症治療＆骨折治療市場規模 … - ヨーロッパ/中東/アフリカの骨粗鬆症治療＆骨折治療市場規模 イギリスの骨粗鬆症治療＆骨折治療市場規模 ドイツの骨粗鬆症治療＆骨折治療市場規模 フランスの骨粗鬆症治療＆骨折治療市場規模 ロシアの骨粗鬆症治療＆骨折治療市場規模 … - その他地域の骨粗鬆症治療＆骨折治療市場規模 ・競争状況 ・企業情報 |
The Global Anti-Osteoporosis Therapy & Fracture Healing Market size was estimated at USD 11.76 billion in 2021 and expected to reach USD 12.73 billion in 2022, and is projected to grow at a CAGR 8.42% to reach USD 19.12 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Anti-Osteoporosis Therapy & Fracture Healing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Alendronate, Biophosphonates, ibandronate, Risedronate, Selective Oestrogen Receptor Modulators, and Zoledronic Acid. The Selective Oestrogen Receptor Modulators is further studied across Raloxifene and Strontium Ranelete.
Based on Route Of Administration, the market was studied across Injectable and Oral.
Based on Distribution, the market was studied across Drug Stores, E-Commerce Market, Hospitals, Private Clinics, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anti-Osteoporosis Therapy & Fracture Healing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Osteoporosis Therapy & Fracture Healing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Osteoporosis Therapy & Fracture Healing Market, including Actavis plc, Amgen Inc., Arthrex, Inc., Bioventus Inc., DJO Global, Inc., Eli Lilly and Company, F.Hoffmann La Roche Ltd., GlaxoSmithKline plc, ISTO Biologics, Johnson & Johnson, Medtronic, plc, Merck and Company Inc., Novartis International AG., Novosteo Inc, Orthofix International N.V., Ossatec Benelux Ltd., Pfizer, Inc., Stryker, Teva Pharmaceutical Industries Ltd., and Zimmer Biomet Holdings, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Anti-Osteoporosis Therapy & Fracture Healing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Osteoporosis Therapy & Fracture Healing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Osteoporosis Therapy & Fracture Healing Market?
4. What is the competitive strategic window for opportunities in the Global Anti-Osteoporosis Therapy & Fracture Healing Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-Osteoporosis Therapy & Fracture Healing Market?
6. What is the market share of the leading vendors in the Global Anti-Osteoporosis Therapy & Fracture Healing Market?
7. What modes and strategic moves are considered suitable for entering the Global Anti-Osteoporosis Therapy & Fracture Healing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising geriatric population worldwide
5.1.1.2. Rapid urbanization coupled with changing lifestyle is increasing the occurrence of bone diseases
5.1.1.3. Growing incidences of post-menopausal osteoporosis in women
5.1.2. Restraints
5.1.2.1. Probable side effects such as nausea, stomach ulcers and irritable bowel syndrome
5.1.3. Opportunities
5.1.3.1. Growing research and development in introduction of new drugs
5.1.3.2. Ongoing awareness of osteoporosis and its impact on health
5.1.4. Challenges
5.1.4.1. High cost of the healing and therapy
5.2. Cumulative Impact of COVID-19
6. Anti-Osteoporosis Therapy & Fracture Healing Market, by Drug
6.1. Introduction
6.2. Alendronate
6.3. Biophosphonates
6.4. ibandronate
6.5. Risedronate
6.6. Selective Oestrogen Receptor Modulators
6.7.1. Raloxifene
6.7.2. Strontium Ranelete
6.7. Zoledronic Acid
7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Distribution
8.1. Introduction
8.2. Drug Stores
8.3. E-Commerce Market
8.4. Hospitals
8.5. Private Clinics
8.6. Retail Pharmacies
9. Americas Anti-Osteoporosis Therapy & Fracture Healing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Anti-Osteoporosis Therapy & Fracture Healing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Actavis plc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Amgen Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Arthrex, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bioventus Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. DJO Global, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Eli Lilly and Company
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. F.Hoffmann La Roche Ltd.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. GlaxoSmithKline plc
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. ISTO Biologics
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Johnson & Johnson
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Medtronic, plc
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Merck and Company Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis International AG.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Novosteo Inc
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Orthofix International N.V.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Ossatec Benelux Ltd.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Pfizer, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Stryker
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Teva Pharmaceutical Industries Ltd.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Zimmer Biomet Holdings, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing